KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Short-Term Debt issuances (2017 - 2025)

BeOne Medicines (ONC) has disclosed Short-Term Debt issuances for 7 consecutive years, with $12.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Short-Term Debt issuances fell 97.77% to $12.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $233.7 million, a 73.09% decrease, with the full-year FY2025 number at $233.7 million, down 73.09% from a year prior.
  • Short-Term Debt issuances was $12.2 million for Q4 2025 at BeOne Medicines, down from $141.5 million in the prior quarter.
  • In the past five years, Short-Term Debt issuances ranged from a high of $543.9 million in Q4 2024 to a low of $768000.0 in Q3 2023.
  • A 5-year average of $136.7 million and a median of $96.2 million in 2022 define the central range for Short-Term Debt issuances.
  • Biggest YoY gain for Short-Term Debt issuances was 820.31% in 2023; the steepest drop was 99.2% in 2023.
  • BeOne Medicines' Short-Term Debt issuances stood at $102.9 million in 2021, then surged by 45.79% to $150.0 million in 2022, then surged by 232.61% to $498.9 million in 2023, then rose by 9.01% to $543.9 million in 2024, then tumbled by 97.77% to $12.2 million in 2025.
  • Per Business Quant, the three most recent readings for ONC's Short-Term Debt issuances are $12.2 million (Q4 2025), $141.5 million (Q2 2025), and $80.0 million (Q1 2025).